Top Markets
Coin of the day
INOVIQ Ltd INOVIQ Ltd

INOVIQ Ltd

IIQ
Rangering i aksjer #29959
INOVIQ Ltd specializes in the research, development, and commercialization of... INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
Aksjekurs
$0.13400411
Markedsverdi
$18.86M
Endring (1 dag)
2.70%
Endring (1 år)
-48.10%
Land
AU
Handel INOVIQ Ltd (IIQ)

Kategori

Inntekter for INOVIQ Ltd (IIQ)
Inntekter i 2026 TTM: 0
Ifølge INOVIQ Ltd sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for INOVIQ Ltd fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$7.61B -
US
$4.76B -
US
- -
CN
$-252.70M -
US
$1.42B -
US